Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBOSCO-LEVY, Pauline
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGOUVERNEUR, Amandine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLANGLADE, Claire
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMIREMONT, Ghada
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.date.accessioned2020-06-02T08:03:20Z
dc.date.available2020-06-02T08:03:20Z
dc.date.issued2019
dc.identifier.issn1879-0518 (Electronic) 0010-7824 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7710
dc.description.abstractEnOBJECTIVE: To compare the risk of all-cause death, hospitalizations (any cause), ectopic pregnancy, pelvic inflammatory disease or infection, uterine perforation, device removal, neuro-psychiatric drugs initiation, or new psychiatric visit(s) between levonorgestrel (LNG) 52mg intrauterine system (IUS) and copper intrauterine device (IUD) users in France. STUDY DESIGN: We identified a historical cohort of women aged 20-55years with a first dispensing of either LNG 52mg IUS or copper-IUD between January 1, 2010 and December 31, 2014, in the French National Claims database, SNDS. We used propensity score matching to balance the two groups on baseline sociodemographic and clinical characteristics to minimize confounding. We estimated Cox proportional hazards models to compare health outcomes between LNG 52mg IUS and copper-IUDs users. RESULTS: We matched 9318 LNG 52mg IUS users (mean age 36.2+/-6.8years) to 10,185 copper-IUD users (mean age 35.4+/-7.1years). After matching and age-adjustment, LNG 52mg IUS users had a slightly higher risk of anxiolytic drugs initiation (HR 1.08, 95%CI 1.01 to 1.15) and device removal (HR 1.05, 95%CI 1.01 to 1.10) compared to copper-IUD users, with no differences for other studied outcomes. CONCLUSION: French IUS users report slightly more anxiolytic treatment initiation and IUD removal compared to copper-IUD users. These results are consistent with a potential pharmacovigilance signal of anxiety-related disorders in LNG 52mg IUS users. IMPLICATIONS STATEMENT: In French LNG 52mg IUS users, there was slightly more anxiolytic treatment initiation and IUD removal compared to copper-IUD users. No risk difference was found for all-cause death, hospitalizations, ectopic pregnancy, pelvic disorders, and uterine perforation. We cannot exclude that the associations are related to differences in characteristics of women who chose each type of type of IUD.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.subject.enCIC1401
dc.title.enSafety of levonorgestrel 52mg intrauterine system compared to copper intrauterine device: a population-based cohort study
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.contraception.2019.02.011en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30871933en_US
bordeaux.journalContraceptionen_US
bordeaux.page345-349en_US
bordeaux.volume99en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03211477
hal.version1
hal.date.transferred2021-04-28T15:19:00Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Contraception&rft.date=2019&rft.volume=99&rft.issue=6&rft.spage=345-349&rft.epage=345-349&rft.eissn=1879-0518%20(Electronic)%200010-7824%20(Linking)&rft.issn=1879-0518%20(Electronic)%200010-7824%20(Linking)&rft.au=BOSCO-LEVY,%20Pauline&GOUVERNEUR,%20Amandine&LANGLADE,%20Claire&MIREMONT,%20Ghada&PARIENTE,%20Antoine&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée